Obesity
Study confirms benefits of Rimonabant in weight loss, waist circumference
Published in Obesity and Diabetes Week, September 27th, 2004
First year results of the 2-year trial Rimonabant In Obesity - Europe (RIO-Europe), a phase III clinical study comparing placebo to rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people taking rimonabant 20mg once daily benefited from a significant reduction in their body weight, waist circumference - a marker of the dangerous abdominal obesity - and improvements in their lipid and glycemic profiles.
The improvement in lipids (HDL-cholesterol and triglycerides) was demonstrated to be partially independent from weight loss, implying a direct effect of the drug on these important...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
More Articles from Obesity and Diabetes Week
- Insulin Resistance
Insulin resistance and the endothelium reviewed - Obesity and Diabetes
Cellular approach to prevent insulin resistance through exercise presented - Obesity and Diabetes
Family of Acrp30/adiponectin structural and functional paralogs reviewed - Obesity and Diabetes
Glucose uptake reduction by peroxynitrite concurrent with receptor nitration - Obesity and Diabetes
Insulin resistance correlated with visceral fat to skeletal muscle ratio - Anorexia Nervosa
Predictors of leptin in adolescent girls with anorexia identified - More from this issue of Obesity and Diabetes Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
